In the present study, the results revealed that the levels of plasma copeptin in patients with cerebral infarction decreased, and the level in the escitalopram treatment group was significantly lower (P<0.05) than that in the control group after three months of treatment. The gene discussed is AVP; the disease is brain infarction.